Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16816913 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL17982719 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL10535250 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL8229978 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL751652 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL4086543 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL210030 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL8528068 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| SCHEMBL443815 | 1.00 | LMNA (0.58) | LMNANR1I2PTGS1ADRA1ABLM | |
| Hydrochloric Acid SCHEMBL6946154 | 0.98 | ALDH1A1 (0.57) | LMNANR1I2PTGS1ADRA1ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085554-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | PROTAGONIST THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3960754-A2 | ALPHA4BETA7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | Protagonist Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210371466-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| EP-3143037-B1 | ALPHA4BETA7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-107709334-B | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-04-13 | — | — | CN | disclosed |
| US-9714270-B2 | a4B7 integrin thioether peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015176035-A1 | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2353714-A1 | ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2011-08-10 | — | — | EP | disclosed |
| WO-2008054233-A2 | PROCESS FOR THE PREPARATION OF DOCETAXEL | INSTYTUT FARMACEUTYCZNY (PL) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | ITGB7, EPCAM, ITGB4 | LMNA 4610/4885NR1I2 2013/4885PTGS1 3098/4885 |
| US-20210371466-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, EPB41 | LMNA 4748/4885NR1I2 1809/4885PTGS1 3336/4885 |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | ITGB7, ITGB4, ITGA4 | LMNA 4741/4885NR1I2 1764/4885PTGS1 2330/4885 |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | AADAT, ALDH7A1, BCAT1 | LMNA 1602/4885NR1I2 3420/4885PTGS1 2002/4885 |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | LMNA 4672/4885NR1I2 1782/4885PTGS1 3491/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | LMNA 4648/4885NR1I2 1851/4885PTGS1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.